Many patients with major depressive disorder (MDD) continue to have residual symptoms despite meeting criteria for remission. The goal of this symposium is to help mental health professionals develop and implement individualized management strategies for patients with MDD. Topics will focus on how to assess and identify residual symptoms using evidence-based screening tools and rating scales, as well as data on newer and emerging treatments.
Psychopharmacology Credit: 1.0
This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.
